NJK14047

NJK14047
Identifiers
  • N-cyclopropyl-3-[4-[4-(2,3-dihydroxypropoxy)benzoyl]phenyl]-4-methylbenzamide
CAS Number
PubChem CID
ChemSpider
Chemical and physical data
FormulaC27H27NO5
Molar mass445.515 g·mol−1
3D model (JSmol)
  • CC1=C(C=C(C=C1)C(=O)NC2CC2)C3=CC=C(C=C3)C(=O)C4=CC=C(C=C4)OCC(CO)O
  • InChI=1S/C27H27NO5/c1-17-2-3-21(27(32)28-22-10-11-22)14-25(17)18-4-6-19(7-5-18)26(31)20-8-12-24(13-9-20)33-16-23(30)15-29/h2-9,12-14,22-23,29-30H,10-11,15-16H2,1H3,(H,28,32)
  • Key:ZQIUCYZGBDPMLG-UHFFFAOYSA-N

NJK14047 is a drug which acts as a selective inhibitor of the enzyme p38 mitogen-activated protein kinase (p38 MAPK). It has antiviral and antiinflammatory effects and was originally developed as a potential treatment for inflammatory lung conditions such as influenza. Subsequent research has also shown promise for various other conditions in which inflammation plays a role, including Alzheimer's disease, asthma, arthritis and psoriasis.[1][2][3][4]

See also

References

  1. ^ Choi MS, Heo J, Yi CM, Ban J, Lee NJ, Lee NR, et al. (August 2016). "A novel p38 mitogen activated protein kinase (MAPK) specific inhibitor suppresses respiratory syncytial virus and influenza A virus replication by inhibiting virus-induced p38 MAPK activation". Biochemical and Biophysical Research Communications. 477 (3): 311–316. doi:10.1016/j.bbrc.2016.06.111. PMID 27346133.
  2. ^ Gee MS, Son SH, Jeon SH, Do J, Kim N, Ju YJ, et al. (April 2020). "A selective p38α/β MAPK inhibitor alleviates neuropathology and cognitive impairment, and modulates microglia function in 5XFAD mouse". Alzheimer's Research & Therapy. 12 (1): 45. doi:10.1186/s13195-020-00617-2. PMC 7175487. PMID 32317025.
  3. ^ Lee JH, Son SH, Kim NJ, Im DS (March 2023). "NJK14047 Suppression of the p38 MAPK Ameliorates OVA-Induced Allergic Asthma during Sensitization and Challenge Periods". Biomolecules & Therapeutics. 31 (2): 183–192. doi:10.4062/biomolther.2022.078. PMC 9970832. PMID 36171179.
  4. ^ Lee JH, Lee JE, Son SE, Son SH, Kim NJ, Im DS (March 2024). "NJK14047 inhibition of p38 MAPK ameliorates inflammatory immune diseases by suppressing T cell differentiation". International Immunopharmacology. 130 111800. doi:10.1016/j.intimp.2024.111800. PMID 38447416.
Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by adding missing information.

Content Disclaimer

Informasi ini disarikan dari Wikipedia dan disajikan kembali untuk tujuan edukasi. Konten tersedia di bawah lisensi CC BY-SA 3.0. Kami tidak bertanggung jawab atas ketidakakuratan data yang bersumber dari kontribusi publik tersebut.

  1. The information displayed on this website is sourced in part or in whole from Wikipedia and has been adapted for the purpose of restating it. We strive to provide accurate and relevant information, however:
  2. There is no guarantee of absolute accuracy. Wikipedia is an open, collaborative project that can be edited by anyone, so information is subject to change.
  3. It is not intended to constitute professional advice. The content displayed is for informational and educational purposes only. For important decisions (e.g., medical, legal, or financial), please consult a professional.
  4. Content copyright. Wikipedia is licensed under the Creative Commons Attribution-ShareAlike License (CC BY-SA). This means that content may be reused with appropriate attribution and shared under a similar license.
  5. Responsible use. Any risk arising from the use of information from this website is entirely the responsibility of the user.